No abstract available
MeSH terms
-
Alemtuzumab / administration & dosage
-
Alemtuzumab / adverse effects
-
Antineoplastic Combined Chemotherapy Protocols / administration & dosage
-
Antineoplastic Combined Chemotherapy Protocols / adverse effects
-
Aprepitant / administration & dosage*
-
Busulfan / administration & dosage
-
Busulfan / adverse effects
-
Busulfan / analogs & derivatives
-
Cyclosporine / administration & dosage
-
Cyclosporine / adverse effects
-
Gastroparesis / drug therapy*
-
Gastroparesis / etiology
-
Gastroparesis / physiopathology
-
Hematopoietic Stem Cell Transplantation / adverse effects*
-
Humans
-
Infant
-
Lymphohistiocytosis, Hemophagocytic / pathology
-
Lymphohistiocytosis, Hemophagocytic / physiopathology
-
Lymphohistiocytosis, Hemophagocytic / therapy
-
Male
-
Methotrexate / administration & dosage
-
Methotrexate / adverse effects
-
Nausea / drug therapy*
-
Nausea / etiology
-
Nausea / physiopathology
-
Unrelated Donors*
-
Vidarabine / administration & dosage
-
Vidarabine / adverse effects
-
Vidarabine / analogs & derivatives
-
Vomiting / drug therapy*
-
Vomiting / etiology
-
Vomiting / physiopathology
Substances
-
Aprepitant
-
Alemtuzumab
-
Cyclosporine
-
treosulfan
-
Vidarabine
-
Busulfan
-
fludarabine
-
Methotrexate